Publicaciones Similares
Biosimilars in Latin America
The regulations for biosimilars vary
considerably from one country to
another, but in general the trend is an
increase in the regulatory standards for their health registration.
Rare Diseases current situation in Latin America and the global drug market
The size of the global market in 2021 for the treatment of rare diseases was valued at USD 119.600 million it is expected to increase at a compound annual growth rate (CAGR) of 12.8% between 2022 and 2030.
Rare Diseases – Orphan drugs- innovative- models of procurement for rare diseases- pricing and reimbursement in Latin America
Orphan drugs used to treat rare diseases have been labeled “orphan drugs” because of their applicability to very small populations, and they respond to public health needs
Why does the Inflation Reduction Act reduce the prices of Pharmaceuticals?
The Inflation Reduction Act (IRA) is used to lower drug prices by imposing extra costs on drug manufacturers that increase their prices above the inflation rate. This forces manufacturers to keep their price increases below the inflation rate to avoid the penalty
Biosimilars in Brazil
Brazil has designed a set of measures to increase investment in biopharmaceutical research and is promoting the production of national biological drugs.
Brazilian Health System
Guarantees universal access to health and finances the system through taxes through the Unified Health System (SUS) and a private sector.